Karyopharm Therapeutics Inc. (KPTI) — Stock Score Summary

Karyopharm Therapeutics Inc. (KPTI) has a MoatMap StockRank of 56/100 based on Quality (21/100), Value (50/100), and Momentum (70/100) factor scores. The current signal is HOLD. Karyopharm is a micro-cap biotech with a weak balance sheet and declining product momentum, representing a highly speculative profile with no margin of safety.

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company dedicated to developing and commercializing novel cancer therapies, primarily focusing on its proprietary nuclear export inhibitors, with XPOVIO as its lead approved product. The company's competitive moat lies in its unique drug class and intellectual property in nuclear export modulation, addressing significant unmet needs in oncology. Karyopharm operates as an innovative biotech, expanding the indications for its approved drug and advancing its pipeline.

Key Financial Metrics

Price$8.69
Market Cap$206M
P/E (Forward)-1.85
Price/Book-0.77
Return on Invested Capital-918.0%
Gross Margin13.5%
Operating Margin-76.3%
Revenue Growth16.8%

Karyopharm Therapeutics Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Karyopharm Therapeutics Inc.’s (KPTI) StockRank?
MoatMap’s StockRank for Karyopharm Therapeutics Inc. (KPTI) is 56/100, with a Hold signal. It is a composite of Quality (21), Value (50), and Momentum (70) factor ranks across MoatMap’s 19,000+ stock universe.
Does Karyopharm Therapeutics Inc. have an economic moat?
Karyopharm Therapeutics Inc. (KPTI) has a Quality factor score of 21/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Karyopharm Therapeutics Inc. a buy, hold, or sell?
MoatMap’s current signal for Karyopharm Therapeutics Inc. (KPTI) is Hold, based on a StockRank of 56/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Karyopharm Therapeutics Inc. in?
Karyopharm Therapeutics Inc. (KPTI) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksKPTI deep dive reportAI ChampionsHow we score stocksSense-check another stock